Photo: Laurie Dieffembacq/Belga/Sipa USA/Sipa via AP Images

Take­da end­ing dis­cov­ery, pre­clin­i­cal work in AAV gene ther­a­py, rare hema­tol­ogy

Take­da told em­ploy­ees re­cent­ly it is end­ing dis­cov­ery and pre­clin­i­cal work in AAV gene ther­a­py as well as re­search and pre­clin­i­cal work on rare hema­tol­ogy, a spokesper­son con­firmed in an emailed state­ment to End­points News.

The move will not im­pact the ex­ist­ing clin­i­cal de­vel­op­ment pipeline or com­mer­cial prod­ucts, the spokesper­son said, not­ing the num­ber of em­ploy­ees im­pact­ed is yet to be de­ter­mined as they might be re­de­ployed to oth­er R&D ar­eas.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.